Hansa Biopharma AB (publ) Stock Forecast for 2023 - 2025 - 2030
Updated on 04/18/2024
Hansa Biopharma AB (publ) Stock Forecast and Price Target
The average price target for Hansa Biopharma AB (publ)'s stock lately set by several renowned analysts is kr94.00, which would result in a potential upside of approximately 218.86% if it reaches this mark by December 31, 2024. This estimation is based on a high estimate of kr174.00 and a low estimate of kr48.00. If you're interested in HNSA stock, it's important to compare it to other companies in the industry.
218.86% Upside
Hansa Biopharma AB (publ) Fair Value Forecast for 2023 - 2025 - 2030
Hansa Biopharma AB (publ)'s Price has seen growth In the last four years, going from kr0.00 to kr0.00 – a gain of 100.00% In the next year, analysts believe that Fair Value will reach kr31.42 – an increase of 100.00%. For the next seven years, the forecast is forFair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SOBI Stock Forecast | Swedish Orphan Biovitrum AB (p... | Outperform |
16
|
kr255.80 | Buy/Sell | kr293.00 | 23.14% |
| VITR Stock Forecast | Vitrolife AB (publ) | Buy |
18
|
kr182.30 | Buy/Sell | kr250.00 | 34.39% |
| BIOA B Stock Forecast | BioArctic AB (publ) | Outperform |
10
|
kr197.00 | Buy/Sell | kr372.40 | 77.66% |
| KARO Stock Forecast | Karo Healthcare AB | - |
12
|
kr60.70 | Buy/Sell | kr40.00 | -100.00% |
| GENO Stock Forecast | Genovis AB (publ.) | Outperform |
16
|
kr28.50 | Buy/Sell | kr75.67 | 94.74% |
Hansa Biopharma AB (publ) Revenue Forecast for 2023 - 2025 - 2030
Hansa Biopharma AB (publ)'s Revenue has seen growth In the last three years, going from kr6.10M to kr134.09M – a gain of 2098.20% In the next year, analysts believe that Revenue will reach kr270.34M – an increase of 101.61%. For the next seven years, the forecast is forRevenue to grow by 11420.80%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VICO Stock Forecast | Vicore Pharma Holding AB (publ... | Buy |
4
|
kr16.12 | Buy/Sell | kr70.75 | 303.23% |
| XSPRAY Stock Forecast | Xspray Pharma AB (publ) | Outperform |
6
|
kr40.70 | Buy/Sell | kr120.00 | 162.90% |
| BINV Stock Forecast | BioInvent International AB (pu... | Outperform |
10
|
kr21.50 | Buy/Sell | kr107.00 | 286.05% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IMMNOV Stock Forecast | Immunovia AB (publ) | - |
0
|
kr1.94 | Buy/Sell | kr0.00 | -100.00% |
| ATORX Stock Forecast | Alligator Bioscience AB (publ) | Outperform |
0
|
kr1.05 | Buy/Sell | kr1.83 | 119.05% |
| CANTA Stock Forecast | Cantargia AB (publ) | Buy |
5
|
kr3.98 | Buy/Sell | kr13.67 | 226.63% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ONCO Stock Forecast | Oncopeptides AB (publ) |
0
|
kr4.47 | Buy/Sell | kr6.90 | 52.13% | |
| KDEV Stock Forecast | Karolinska Development AB (pub... |
8
|
kr1.52 | Buy/Sell | kr4.70 | 166.45% | |
| ISR Stock Forecast | ISR Immune System Regulation H... | - |
0
|
kr7.43 | Buy/Sell | kr0.00 | -100.00% |
Hansa Biopharma AB (publ) EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Hansa Biopharma AB (publ)'s EBITDA has increased by 86.10%, going from kr-422.40M to kr-786.09M. In the next year, 4 analysts estimate that Hansa Biopharma AB (publ)'s EBITDA will decrease by 19.21%, reaching kr-635.09M. According to professional forecasts, in 2030, Hansa Biopharma AB (publ)'s EBITDA will decrease by 111.53%, reaching kr90.63M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IMMU Stock Forecast | Mendus AB (publ) |
9
|
kr0.51 | Buy/Sell | kr1.70 | 252.94% | |
| IVACC Stock Forecast | Intervacc AB (publ) |
10
|
kr4.15 | Buy/Sell | kr27.00 | 92.77% | |
| CLBIO Stock Forecast | Corline Biomedical AB |
6
|
kr11.00 | Buy/Sell | kr35.00 | 190.91% |
Hansa Biopharma AB (publ) EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Hansa Biopharma AB (publ)'s EBIT has grown, increasing from kr-425.08M to kr-788.50M – an increase of 85.49%. According to 6 analysts, Hansa Biopharma AB (publ)'s EBIT will fall by 12.26% in the next year, reaching kr-691.86M. Professionals believe that By 2030, Hansa Biopharma AB (publ)'s EBIT will fall to kr11.35B – a 1539.87% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ACE Stock Forecast | Ascelia Pharma AB (publ) |
0
|
kr13.90 | Buy/Sell | kr19.50 | -29.86% | |
| NICA Stock Forecast | Nanologica AB (publ) |
0
|
kr5.70 | Buy/Sell | kr14.75 | 110.53% | |
| SYNACT Stock Forecast | SynAct Pharma AB | - |
7
|
kr6.82 | Buy/Sell | kr15.00 | -100.00% |
Hansa Biopharma AB (publ) EPS Price Prediction Forecast for 2023 - 2025 - 2030
Hansa Biopharma AB (publ)'s EPS has seen growth In the last four years, going from kr-9.98 to kr0.00 – a gain of 100.00% In the next year, analysts believe that EPS will reach kr-11.20 – an increase of 100.00%. For the next seven years, the forecast is forEPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NXTCL Stock Forecast | NextCell Pharma AB | - |
0
|
kr2.48 | Buy/Sell | kr0.00 | -100.00% |
| GUARD Stock Forecast | Guard Therapeutics Internation... |
8
|
kr27.20 | Buy/Sell | kr0.23 | 138.97% | |
| VIVE Stock Forecast | Vivesto AB | - |
0
|
kr0.32 | Buy/Sell | kr0.95 | -100.00% |
Site Navigation
.jpg)